Medication Affordability and Patent Integrity Act
Bill Summary
Requires pharmaceutical companies to justify price increases for certain medications and limits the ability to extend patents, which can delay generic versions from entering the market. Funds are not directly allocated, but the goal is to make medications more affordable.
Sponsored By
Bill Journey
- Aug 1, 2025
- Jun 17, 2026You Are Here
The committee will review the bill, debate amendments, and vote on whether to advance it to the full chamber.
- TBD
The full chamber debates the bill, may amend it, and votes on whether to pass it.
- TBD
If passed by the first chamber, the other chamber considers, may amend, and votes on the bill.
- TBD
If passed by both chambers, the bill goes to the President to sign into law or veto.
Why It Matters
This bill affects people who rely on prescription medications, particularly those with expensive or hard-to-find treatments, by potentially reducing their out-of-pocket costs. It also impacts pharmaceutical companies, which may face increased scrutiny and limitations on their pricing and patent strategies.
Impact Areas
Support & Opposition
- Democratic1
- Republican1
Documents
1
Full text opens on congress.gov, the official source.
Cosponsors (1)
Bill Details
- Economy
Summary and impact analysis written by Judy (KnowGov's enrichment AI). Bill metadata, status, sponsor, and any floor votes from Prism. Sections marked “Sample” are placeholders not yet connected to live data.